Pacific Biosciences
PACB
226 hedge funds and large institutions have $1.23B invested in Pacific Biosciences in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 61 increasing their positions, 70 reducing their positions, and 40 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
20% more capital invested
Capital invested by funds: $1.03B → $1.23B (+$202M)
1% less funds holding
Funds holding: 228 → 226 (-2)
3% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 40
6.28% less ownership
Funds ownership: 100.48% → 94.2% (-6.3%)
13% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 70
42% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $20M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.5M |
| 2 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$17.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.5M |
| 4 |
DM
Deerfield Management
New York
|
+$11.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$39.7M |
| 2 |
Goldman Sachs
New York
|
-$27.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$24.8M |
| 4 |
Two Sigma Investments
New York
|
-$19.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$17.9M |
PACB Hedge Fund Activity: Q3 2022 in Review
226 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2022, worth a combined $1.23B — up 20% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PACB and 39 opened new positions — a net loss of 1 holder — while 70 trimmed existing stakes and 61 added.
The largest buyer was Citadel Advisors, adding an estimated $26.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $39.7M.
- 226 institutional investors held Pacific Biosciences (PACB) as of Q3 2022, down from 228 in Q2 2022.
- Funds reported $1.23B of Pacific Biosciences stock for Q3 2022, up 20% quarter-over-quarter.
- 39 funds opened new Pacific Biosciences positions in Q3 2022 and 40 closed out, a net change of -1 holder.
- The largest Pacific Biosciences buyer in Q3 2022 was Citadel Advisors, an estimated $26.5M added.
- The largest Pacific Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $39.7M sold.
Based on aggregated 13F filings for Q3 2022.